XBP1 and viral infectious disease: This VACV infection-associated decrease in XBP1 mRNA splicing is so remarkable that virus infection is able to counteract the tunicamycin-induced XBP1 splicing, considering that the drug is a potent inducer of UPR activation and IRE1α activation.